Dan MacHugh: From Bench to Boardroom
In this episode of Precision Signals, Sean Khozin speaks with Dan McHugh, investor at Yosemite, about the systems that mediate between scientific discovery and patient impact. Dan’s path runs from Stanford bioengineering and the Greenleaf Lab to Bain & Company, Emerson Collective, and the co-founding of Tune Therapeutics. Across these roles, he has operated at the boundary between deep biological science and the capital and policy structures that determine whether that science ultimately reaches patients.
The conversation examines how incentives, reimbursement, and regulation shape the fate of cancer therapies, sometimes in rather unpredictable ways. It also explores Yosemite’s founding by Reed Jobs, Dan’s longstanding friendship with him, and how trust, time horizon, and shared mission have shaped a hybrid model that combines venture investment with grant-based risk-taking.
This is a discussion about cancer, but it is equally a discussion about architecture: how systems are designed and what they reward.
